01861-A: Preventing Heart Damage during Chemotherapy through Early Detection of Cardiotoxicity
Doxorubicin is a commonly used chemotheraputic agent in veterinary oncology with efficacy in the treatment of many cancer types. It has been well documented that doxorubicin can cause toxic changes to the heart that can result in heart failure and even death. Abnormal heart rhythms can also occur, however in veterinary medicine, the extent of […]
00678: Generation and Analysis of Canine Bone Marrow Derived Mast Cells
Disorders of mast cells, particularly mast cell tumors (MCTs), are common in dogs and there is now evidence that many of these exhibit breed specific tendencies, suggesting underlying genetic causes. This is particularly important for MCTs in which certain breeds (e.g., Pugs) develop benign disease while others (e.g., Chinese Shar-Pei) develop malignant disease. In comparison […]
01093A: Positional Cloning of the Gene(s) for Gastric Cancer in the Chow Chow
Several canine breeds including Chow Chows, Belgian Sheepdogs and Tervuren, Keeshonden, Norwegian elkhounds, Akitas, Eurasiers, and Scottish Terriers have an increased risk on developing gastric carcinoma (stomach cancer). Furthermore, examination of pedigrees suggests that this cancer may result from a faulty gene or genes. Our goal is to identify the gene(s) that predispose this cancer […]
01336B: Finding the Mutations that Increase Susceptibility to Transitional Cell Carcinoma in the Scottish Terrier, West Highland Terrier, and Shetland Sheepdog
Cancer is a major cause of death in older dogs and treatment of the disease is often ineffective. We wish to identify the causes of cancer in order to learn how to more effectively predict, prevent, and treat the disease. Genetic (heritable) factors are important in development of Transitional cell carcinoma (TCC) of the bladder. […]
00878-A: MicroRNA Expression in the Domestic Dog and Its Role in Canine Cancer
A new group of genes, termed microRNAs, have been discovered to be associated with various cancers in the human. These genes are also found in dogs and have the exact same sequence as the human counterparts. Due to the great similarity between the human and dog, we hypothesize that these genes may also play a […]
02732-A: Tumor-educated Platelets: A Novel Minimally Invasive Liquid Biopsy for Early Cancer Diagnosis
Platelets are a vital part of the blood clotting system and interact closely with tumor cells. These interactions promote tumor growth and spread, but also alter the RNA content of platelets. These altered platelets are described as tumor-educated platelets because they carry this tumor signature to distant sites as they circulate through the body. RNA […]
0002214T: Identification of a 5-10Mb BAC Set as a Cytogenetic Resource and for the Development of an Ordered CGH Microarray for Cancer Studies in the Dog
The study of aberrant chromosome structure has significantly increased our understanding of the cause and progression of human cancers. Many cancers are common to both dogs and humans, in part reflecting the high degree of similarity in their genetic material and in their environmental exposure to carcinogens. The extent and identity of chromosome aberrations associated […]
02522-A: The Investigation of Lypoxigenase-5 Expression in Canine Normal, Hyperplastic and Neoplastic Urinary Bladder Epithelium
Transitional Cell Carcinoma (TCC) is the most common tumor of the canine urinary tract, causing nonresolving urinary signs (i.e., straining, hematuria) after it invades a large portion of the bladder and/or neighboring structures. Surgery may not be an option and chemotherapy represents the most common treatment; however, significant tumor reduction rarely occurs, resulting in a […]
01912-A: Enhancing the Safety and Efficacy of Anti-Cancer Drugs in Dogs
The anti-cancer drugs doxorubicin and daunorubicin are used to treat a wide variety of cancers in dogs. The clinical utilization of these drugs is hampered by the development of cardiotoxicity in 69% of canine patients. Dr. Blanco will investigate a potential causative agent behind drug-related cardiotoxicity: the enzyme Carbonyl reductase 1 (CBR1). Dr. Blanco will […]
02171-MOU: Histiocytic Sarcoma in Bernese Mountain Dogs: Novel Approaches To Treatment
Canine histiocytic sarcoma (HS) is a highly aggressive cancer that affects Bernese Mountain Dogs (BMD), with a particularly high prevalence rate that ranges from 15 to 25% of the population. The current treatment options for HS are based on the administration of conventional chemotherapeutic drugs, to which dogs respond poorly and only for a short […]